Evaluation of the Cost in Patients with Chronic Obstructive Pulmonary Disease (COPD) Within the Public Health Perspective in Mexico

Author(s)

Zenteno RDJ1, Lemus Rangel R2, Martínez Pacheco V3, Guzman Vazquez S4, Soto Molina H3, Juarez K3, Marin Aguilar MM3
1Instituto Nacional de Enfermedades Respiratorias (INER), Mexico city, Mexico, 2Hospital General Dr. Gaudencio González Garza, Centro Medico Nacional "La Raza" IMSS., Ciudad de México, Mexico, 3HS Estudios Farmacoeconómicos S.A. de C.V., Mexico city, Mexico, 4Agencia Mexicana de Evaluación de Tecnologías Sanitarias AC, Iztapalapa, Mexico

Objective: To estimate the cost of care of patients with chronic obstructive pulmonary disease (COPD) with stable disease and exacerbations in Mexico.

Methods: A cost of care analysis of COPD patients was performed from an institutional point of view. Only average direct medical costs per patient, adjusted by GOLD classification, were estimated. Resource utilization was obtained from a panel of medical experts belonging to the National Health System in Mexico, using Delphi methodology, where the therapeutic options, recommended doses, as well as the use of hospital resources in the treatment of controlled patients and patients with exacerbations by Gold classification, used in their clinical practice, were validated. Costs were obtained from public health sources. The costing was carried out using the micro-costing technique and a time horizon of 1 year was considered; the results are expressed in USD.

Results: The average cost of diagnosis was $1,255.99 USD. The estimated average cost of patients with COPD in control was $1,500.36, $2,157.59, $3,442.05 and $5,109.57 for Gold 1,2,3 and 4 categories respectively, on the other hand, the average cost of patients with exacerbation for each category was $1,164.42, $3,460.41, $9,199.12 and $23,717.99 respectively. The results show that there is an increase in costs with increasing disease severity category and treatment of exacerbations accounts for most of the economic burden.

Conclusions: The difference in costs between categories was due to the cost of hospitalizations, intensive care, and oxygen use. Timely diagnosis of COPD and medical care to keep patients in control in the first categories of the disease, maintain them stable and prevent exacerbations would represent a reduction in the burden of the disease for the public sector.

Conference/Value in Health Info

2022-05, ISPOR 2022, Washington, DC, USA

Value in Health, Volume 25, Issue 6, S1 (June 2022)

Code

EE26

Topic

Clinical Outcomes, Economic Evaluation, Study Approaches

Topic Subcategory

Clinician Reported Outcomes, Surveys & Expert Panels

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×